PMID- 35899169
OWN - NLM
STAT- MEDLINE
DCOM- 20220729
LR  - 20220813
IS  - 2296-2565 (Electronic)
IS  - 2296-2565 (Linking)
VI  - 10
DP  - 2022
TI  - Oral Adverse Events Following COVID-19 Vaccination: Analysis of VAERS Reports.
PG  - 952781
LID - 10.3389/fpubh.2022.952781 [doi]
LID - 952781
AB  - BACKGROUND: Oral adverse events (AEs) following COVID-19 vaccination have been 
      sporadically reported during the previous months, warranting further 
      investigation for their prevalence and suspected relationship with 
      vaccine-elicited immune response. METHODS: A retrospective analysis using the 
      Vaccine Adverse Event Reporting System (VAERS) data was conducted to evaluate AEs 
      within the oral cavity (mucosa, tongue, lips, palate, dentition, salivary glands) 
      and AEs involving taste and other sensations. Oral AEs reported after receiving 
      COVID-19 vaccination (test group) and seasonal influenza vaccination (control 
      group) were extracted and cross-tabulated to assess their relative prevalence. 
      RESULTS: Among the 128 solicited (suspected) oral AEs, oral paresthesia (0.872%) 
      was most reported after receiving COVID-19 vaccines, followed by the swelling of 
      lips (0.844%), ageusia (0.722%), oral hypoesthesia (0.648%), swollen tongue 
      (0.628%), and dysgeusia (0.617%). The reported prevalence of oral AEs was higher 
      in the COVID-19 vaccine group than in the seasonal influenza group. The 
      distribution pattern of the most reported oral AEs was similar for both COVID-19 
      and seasonal influenza vaccines. Female sex, older age (>39 years old), primer 
      doses, and mRNA-based COVID-19 vaccines exhibited a higher reported prevalence of 
      oral AEs. CONCLUSION: Within the limitations of this study, COVID-19 vaccines 
      were found to be associated with rare oral AEs that are predominantly similar to 
      those emerging following seasonal influenza vaccines. The most commonly reported 
      oral AEs were oral paraesthesia (mouth-tingling), lip swelling, and ageusia, 
      representing various pathophysiologic pathways that remain unclear. Taste-related 
      AEs should be acknowledged in the context of the COVID-19 pandemic and the public 
      should be adequately informed about a potential taste dysfunction after receiving 
      the COVID-19 vaccination. Dentists and dental teams need to be aware of the 
      prevalence, severity, and prognosis of oral AEs to inform their patients and 
      increase public confidence in vaccines.
CI  - Copyright (c) 2022 Riad, Pold, Kateeb and Attia.
FAU - Riad, Abanoub
AU  - Riad A
AD  - Department of Public Health, Faculty of Medicine, Masaryk University, Brno, 
      Czechia.
FAU - Pold, Ave
AU  - Pold A
AD  - Department of Oral, Dental and Maxillofacial Diseases, University Hospital 
      Heidelberg, Heidelberg, Germany.
FAU - Kateeb, Elham
AU  - Kateeb E
AD  - Oral Health Research and Promotion Unit, Al-Quds University, Jerusalem, 
      Palestine.
AD  - Public Policy Center, The University of Iowa, Iowa City, IA, United States.
FAU - Attia, Sameh
AU  - Attia S
AD  - Department of Oral and Maxillofacial Surgery, Justus-Liebig-University, Giessen, 
      Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220711
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Influenza Vaccines)
SB  - IM
MH  - Adult
MH  - Adverse Drug Reaction Reporting Systems
MH  - *Ageusia/chemically induced
MH  - *COVID-19/epidemiology/prevention & control
MH  - *COVID-19 Vaccines/adverse effects
MH  - Female
MH  - Humans
MH  - *Influenza Vaccines/adverse effects
MH  - *Influenza, Human
MH  - Pandemics
MH  - Retrospective Studies
MH  - Vaccination
PMC - PMC9309565
OTO - NOTNLM
OT  - COVID-19 vaccines
OT  - anaphylaxis
OT  - drug-related side effects and adverse reactions
OT  - oral manifestations
OT  - pharmacovigilance oral adverse events following COVID-19 vaccination 2
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/07/29 06:00
MHDA- 2022/07/30 06:00
PMCR- 2022/07/11
CRDT- 2022/07/28 02:23
PHST- 2022/05/25 00:00 [received]
PHST- 2022/06/22 00:00 [accepted]
PHST- 2022/07/28 02:23 [entrez]
PHST- 2022/07/29 06:00 [pubmed]
PHST- 2022/07/30 06:00 [medline]
PHST- 2022/07/11 00:00 [pmc-release]
AID - 10.3389/fpubh.2022.952781 [doi]
PST - epublish
SO  - Front Public Health. 2022 Jul 11;10:952781. doi: 10.3389/fpubh.2022.952781. 
      eCollection 2022.